Loading patent…
AssigneeTakeda Pharmaceutical Company Limited
InventorsWei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Dalgarno, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela V. West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou
Estimating the term…
Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
A method for treating non-small cell lung cancer (NSCLC) with one or more insertion mutations in the exon 20 domain of the epidermal growth factor receptor (EGFR) comprising administering to a subject in need thereof, a therapeutically effective amount of Compound (I) having the following structure:
A method for inhibiting EGER with one or more insertion mutations in the exon 20 domain in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of Compound (I) having the following structure:
Dependencies are inferred from the claim text.